Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NTRA NYSE:NVTA NASDAQ:RDNT NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTRANatera$194.24-11.6%$202.23$131.81▼$256.36$31.28B1.571.45 million shs3.92 million shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shsN/ARDNTRadNet$58.19+1.2%$60.26$50.76▼$85.84$4.50B1.43775,574 shs1.46 million shsVCYTVeracyte$40.42-0.8%$33.54$22.61▼$50.71$3.25B1.89923,636 shs1.16 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTRANatera0.00%+6.63%+4.26%+8.26%+37.30%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet0.00%+1.68%+2.84%-16.96%+4.80%VCYTVeracyte0.00%+23.82%+24.76%+12.63%+32.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTRANatera$194.24-11.6%$202.23$131.81▼$256.36$31.28B1.571.45 million shs3.92 million shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shsN/ARDNTRadNet$58.19+1.2%$60.26$50.76▼$85.84$4.50B1.43775,574 shs1.46 million shsVCYTVeracyte$40.42-0.8%$33.54$22.61▼$50.71$3.25B1.89923,636 shs1.16 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTRANatera0.00%+6.63%+4.26%+8.26%+37.30%NVTAInvitae0.00%0.00%0.00%0.00%0.00%RDNTRadNet0.00%+1.68%+2.84%-16.96%+4.80%VCYTVeracyte0.00%+23.82%+24.76%+12.63%+32.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNTRANatera 2.79Moderate Buy$256.0031.80% UpsideNVTAInvitae 0.00N/AN/AN/ARDNTRadNet 2.90Moderate Buy$88.1451.47% UpsideVCYTVeracyte 2.38Hold$44.8310.92% UpsideCurrent Analyst Ratings BreakdownLatest NTRA, NVTA, VCYT, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026NTRANatera Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$265.005/8/2026NTRANatera EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$270.005/8/2026NTRANatera JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$260.00 ➝ $265.005/8/2026NTRANatera Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$215.00 ➝ $220.005/6/2026VCYTVeracyte UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $52.005/6/2026VCYTVeracyte Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$40.00 ➝ $42.004/21/2026NTRANatera Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026RDNTRadNet BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$86.00 ➝ $70.004/20/2026VCYTVeracyte Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$43.00 ➝ $40.004/14/2026NTRANatera William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/13/2026VCYTVeracyte Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNTRANatera$2.31B11.99N/AN/A$12.38 per share15.69NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00RDNTRadNet$2.04B2.23$3.26 per share17.84$17.58 per share3.31VCYTVeracyte$517.15M6.24$1.48 per share27.36$16.85 per share2.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNTRANatera-$208.16M-$1.53N/A19,424.00N/A-9.05%-15.72%-11.07%N/ANVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/ARDNTRadNet-$18.65M-$0.25N/A53.88N/A-0.91%2.52%0.88%5/10/2026 (Estimated)VCYTVeracyte$66.35M$1.0937.0830.16N/A16.25%9.07%8.38%N/ALatest NTRA, NVTA, VCYT, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/10/2026Q1 2026RDNTRadNet-$0.1643N/AN/AN/A$557.93 millionN/A5/5/2026Q1 2026VCYTVeracyte$0.34$0.52+$0.18$0.35$130.36 million$139.07 million3/2/2026Q4 2025RDNTRadNet$0.19$0.23+$0.04-$0.01$515.67 million$547.71 million2/26/2026Q4 2025NTRANatera-$0.46$0.35+$0.81$0.36$600.68 million$665.50 million2/25/2026Q4 2025VCYTVeracyte$0.41$0.53+$0.12$0.51$135.79 million$140.64 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNTRANateraN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNTRANateraN/A3.393.24NVTAInvitaeN/A2.392.25RDNTRadNet0.791.761.76VCYTVeracyteN/A9.317.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNTRANatera99.90%NVTAInvitae61.28%RDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipNTRANatera5.63%NVTAInvitae0.74%RDNTRadNet5.60%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNTRANatera6,140142.30 million134.29 millionOptionableNVTAInvitae1,700267.01 million284.37 millionNo DataRDNTRadNet11,26478.27 million73.89 millionOptionableVCYTVeracyte79079.79 million78.68 millionOptionableNTRA, NVTA, VCYT, and RDNT HeadlinesRecent News About These CompaniesInsider Selling: Veracyte (NASDAQ:VCYT) SVP Sells 10,204 Shares of Stock4 hours ago | insidertrades.comAnalysts Are Bullish on These Healthcare Stocks: Veracyte (VCYT), Solventum Corporation (SOLV)May 8 at 11:24 PM | theglobeandmail.comVeracyte (NASDAQ:VCYT) SVP Sells $398,160.08 in StockMay 8 at 5:19 PM | marketbeat.comVeracyte Inc Earnings Call Signals Profitable GrowthMay 8 at 1:24 PM | theglobeandmail.comVeracyte, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen NextMay 8 at 1:24 PM | finance.yahoo.comWhy Veracyte Stock Is Skyrocketing Higher This WeekMay 7 at 12:51 AM | fool.comVeracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for InvestorsMay 7 at 10:31 AM | zacks.comVeracyte (NASDAQ:VCYT) Shares Gap Up Following Strong EarningsMay 6 at 10:21 AM | marketbeat.comVeracyte earnings loom: Investors watch for TrueMRD launch detailsMay 6 at 8:59 AM | investing.comVeracyte: Q1 Earnings SnapshotMay 5, 2026 | sfgate.comVeracyte (VCYT) Q1 2026 Earnings TranscriptMay 5, 2026 | finance.yahoo.comVeracyte Q1 Earnings Call HighlightsMay 5, 2026 | marketbeat.comVeracyte, Inc. (VCYT) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comVeracyte (VCYT) Beats Q1 Earnings and Revenue EstimatesMay 5, 2026 | zacks.comVeracyte (NASDAQ:VCYT) Issues Quarterly Earnings ResultsMay 5, 2026 | marketbeat.comVeracyte Announces First Quarter 2026 Financial ResultsMay 5, 2026 | businesswire.comWall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a BetMay 5, 2026 | zacks.comA Look At Veracyte (VCYT) Valuation As New Decipher Bladder And Prostate Data Heads To AUA 2026May 4, 2026 | finance.yahoo.comVeracyte (VCYT) Projected to Post Quarterly Earnings on TuesdayMay 3, 2026 | americanbankingnews.comIf you invested $1000 in Veracyte a decade ago, this is how much it'd be worth nowApril 29, 2026 | msn.comVeracyte (VCYT) to Release Earnings on TuesdayApril 28, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThese 3 Defense Giants Beat Q1 Estimates—So Why Did Their Stocks Still Fall?By Jessica Mitacek | April 22, 2026Corning Beats Q1 Estimates but Drops 9% on Guidance MissBy Ryan Hasson | April 29, 202695% Options Surge: Smart Money Bets Big on a Super Micro Bounce By Jeffrey Neal Johnson | April 15, 2026Up 775% in 5 Months, How Much Higher Can Syntec Optics Go?By Thomas Hughes | April 21, 2026Microsoft Targets Trimmed: What It Means for InvestorsBy Chris Markoch | April 20, 2026NTRA, NVTA, VCYT, and RDNT Company DescriptionsNatera NASDAQ:NTRA$194.24 -25.58 (-11.64%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$195.23 +0.99 (+0.51%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.RadNet NASDAQ:RDNT$58.19 +0.69 (+1.20%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$60.52 +2.33 (+4.00%) As of 05/8/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$40.42 -0.34 (-0.83%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$40.42 -0.01 (-0.01%) As of 05/8/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
